Eli Lilly and Company, together with partner Innovent Biologics, announced today that China’s National Medical Products Administration will review its application for IBI301, a proposed rituximab biosimilar referencing MabThera and Rituxan.
Eli Lilly and Company, together with partner Innovent Biologics, announced today that China’s National Medical Products Administration will review its application for IBI301, a proposed rituximab biosimilar referencing MabThera and Rituxan.
According to the partnership, the biosimilar has the opportunity to increase access for Chinese patients; despite a high unmet demand for effective cancer treatments, use of rituximab remains relatively low due to its high cost.
Li Wang, MD, PhD, senior vice president of Lilly China and head of Lilly China drug development and medical affairs, said of the submission in a statement, "The NDA of IBI301 represents another millstone of strategic cooperation between Lilly and Innovent. We hope that IBI301 can be approved soon in order to offer an affordable treatment option for lymphoma patients in China."
Last month, the partnership announced that 2 studies of the biosimilar had met their primary end points. The first, a single-dose study, assessed the pharmacokinetics, safety, tolerability, and immunogenicity of the biosimilar versus the reference drug in 181 patients with CD20-positive B-cell lymphoma. The drug makers reported that the study met its primary end point, area under the concentration—time curve from time zero to infinity, over a time frame of 91 days.
The second study, a phase 3 trial in 420 patients with diffuse large B-cell lymphoma who received either the biosimilar or the reference drug in combination with standard chemotherapy for 6 cycles as first-line treatment for newly diagnosed disease, met its primary end point of overall response rate over a time frame of 18 weeks.
If approved, Lilly and Innovent’s rituximab will join 1 other approved biosimilar rituximab product in the Chinese marketplace; in February 2019, China approved Henlius’ HLX01. Approval of this rituximab product was a milestone for the Chinese market, as it was not only the first rituximab biosimilar to be approved in the market, but also the first biosimilar to be cleared under the country’s biosimilar approval pathway.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.